Second Cancers after Breast Cancer Treatment

Seminars in Oncology

Volumn 30, Issue 6, 2003, Pages 740-748

  Matesich, Mary Andrew ^a   Shapiro, Charles L ^a,b  

^a Department of Medicine ^*

^b THE OHIO STATE UNIVERSITY WEXNER MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALKYLATING AGENT; ANASTROZOLE; CHLORAMBUCIL; CYCLOPHOSPHAMIDE; DOXORUBICIN; EPIRUBICIN; FLUOROURACIL; MELPHALAN; METHOTREXATE; RALOXIFENE; TAMOXIFEN;

ACUTE GRANULOCYTIC LEUKEMIA; BREAST CARCINOMA; CANCER ADJUVANT THERAPY; CANCER HORMONE THERAPY; CANCER RADIOTHERAPY; CANCER RISK; DOSE RESPONSE; ENDOMETRIUM CARCINOMA; HUMAN; LATENT PERIOD; LEUKEMIA; LUNG CARCINOMA; MASTECTOMY; MYELODYSPLASTIC SYNDROME; PRIORITY JOURNAL; RADIATION DOSE; REVIEW; RISK FACTOR; SARCOMA; SECOND CANCER; SOLID TUMOR; TREATMENT PLANNING;

EID: 0346363702     PISSN: 00937754     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.seminoncol.2003.08.022     Document Type: Article

References (79)

1. Shapiro CL, Recht A: Late effects of adjuvant therapy for breast cancer. JNCI Monogr 16:101-112, 1994
2. Shapiro CL, Recht A: Side effects of adjuvant treatment of breast cancer. N Engl J Med 344:1997-2008, 2001
3. Hayden GF, Kramer MS, Horwitz RI: The case-control study. A practical review for the clinician. JAMA 247:326-331, 1982
4. Fisher B, Rockette H, Fisher ER, et al: Leukemia in breast cancer patients following adjuvant chemotherapy or postoperative radiation: The NSABP experience. J Clin Oncol 3:1640-1658, 1985
5. Whelan TJ, Julian J, Wright J, et al: Does locoregional radiation therapy improve survival in breast cancer? A meta-analysis. J Clin Oncol 18:1220-1229, 2000
6. Harris JR, Halpin-Murphy P, McNeese M, et al: Consensus statement on postmastectomy radiation therapy. Int J Radiat Oncol Biol Phys 44:989-990, 1999
7. Favourable and unfavourable effects on long-term survival of radiotherapy for early breast cancer: An overview of the randomised trials. Early Breast Cancer Trialists' Collaborative Group. Lancet 355:1757-1770, 2000
8. Fisher B, Jeong J-H, Anderson S, et al: Twenty-five-year follow-up of a randomized trial comparing radical mastectomy, total mastectomy, and total mastectomy followed by irradiation. N Engl J Med 347:567-575, 2002
9. Veronesi U, Cascinelli N, Mariani L, et al: Twenty-year follow-up of a randomized study comparing breast-conserving surgery with radical mastectomy for early breast cancer. N Engl J Med 347:1227-1232, 2002
10. Fisher B, Anderson S, Bryant J, et al: Twenty-year follow-up of a randomized trial comparing total mastectomy, lumpectomy, and lumpectomy, plus irradiation for the treatment of invasive breast cancer. N Engl J Med 347:1233-1241, 2002
11. Fisher B, Dignam J, Wolmark N, et al: Lumpectomy and radiation therapy for the treatment of intraductal breast cancer: Findings from National Surgical Adjuvant Breast and Bowel Project B-17. J Clin Oncol 16:441-452, 1998
12. Galper S, Gelman R, Recht A, et al: Second nonbreast malignancies after conservative surgery and radiation therapy for early-stage breast cancer. Int J Radiat Oncol Biol Phys 52:406-414, 2002
13. Fowble B, Hanlon A, Freedman G, et al: Second cancers after conservative surgery and radiation for stages I-II breast cancer: Identifying a subset of women at increased risk. Int J Radiat Oncol Biol Phys 51:679-690, 2001
14. Obedian E, Fischer DB, Haffty BG: Second malignancies after treatment of early-stage breast cancer: Lumpectomy and radiation therapy versus mastectomy. J Clin Oncol 18: 2406-2412, 2000
15. Rubino C, de Vathaire F, Diallo I, et al: Increased risk of second cancers following breast cancer: Role of the initial treatment. Breast Cancer Res Treat 61:183-195, 2000
16. Fraass BA, Roberson PL, Lichter AS: Dose to the contralateral breast due to primary breast irradiation. Int J Radiat Oncol Biol Phys 11:485-497, 1985
17. Storm HH, Anderson M, Boice JD, et al: Adjuvant radiotherapy and risk of contralateral breast cancer. J Natl Cancer Inst 84:1245-1250, 1992
18. Boice JD, Harvey EB, Blettner M, et al: Cancer in the contralateral breast after radiotherapy for breast cancer. N Engl J Med 326:781-785, 1992
19. Hankey BF, Curtis RE, Naughton MD, et al: A retrospective cohort analysis of second breast cancer risk for primary breast cancer patients with an assessment of the effect of radiation therapy. J Natl Cancer Inst 70:797-804, 1983
20. Shapiro CL, Mauch PM: Radiation-associated breast cancer after Hodgkin's disease: Risks and screening in perspective. J Clin Oncol 10:1662-1665, 1992
21. Morrow MH Jr: Local management of invasive cancer, in Harris J, Lippman ME, Morrow M et al (eds): Diseases of the Breast. Philadelphia, PA, Lippincott Williams & Wilkins, 2001, pp 515-560
22. Neugut Al, Weinberg MD, Ahsan H, et al: Carcinogenic effects of radiotherapy for breast cancer. Oncology (Huntington) 13:1245-1256, 1999
23. Curtis RE, Boice JD, Stovall M, et al: Leukemia risk following radiotherapy for breast cancer. J Clin Oncol 7:21-29, 1989
24. Chaplain G, Milan C, Sgro C, et al: Increased risk of acute leukemia after adjuvant chemotherapy for breast cancer: A population-based study. J Clin Oncol 18:2836-2842, 2000
25. Curtis RE, Boice JC, Stovall M, et al: Risk of leukemia after chemotherapy and radiation treatment for breast cancer. N Engl J Med 326:1745-1751, 1992
26. Smith RE, Bryant J, DeCillis A, et al: Acute myeloid leukemia and myelodysplastic syndrome after doxorubicin-cyclophosphamide adjuvant therapy for operable breast cancer: The National Surgical Adjuvant Breast and Bowel Project experience. J Clin Oncol 21:1195-1204, 2003
27. Taghian A, de Vathaire F, Terrier P, et al: Long-term risk of sarcoma following radiation treatment for breast cancer. Int J Radiat Oncol Biol Phys 21:361-367, 1991
28. Yap J, Chuba PJ, Thomas R, et al: Sarcoma as a second malignancy after treatment for breast cancer. Int J Radiat Oncol Biol Phys 52:1231-1237, 2002
29. Marchal C, Weber B, de Lafontan B, et al: Nine breast angiosarcomas after conservative treatment for breast carcinoma: A survey from French Comprehensive Cancer Centers. Int J Radiat Oncol Biol Phys 44:113-119, 1999
30. Strobbe LJA, Peterse HL, van Tinteren H, et al: Angiosarcoma of the breast after conservation therapy for invasive cancer, the incidence and outcome. An unforseen sequela. Breast Cancer Res Treat 47:101-109, 1998
31. Neugut Al, Robinson E, Lee WC, et al: Lung cancer after radiation therapy for breast cancer. Cancer 71:3054-3057, 1993
32. Neugut Al, Murray T, Santos J, et al: Increased risk of lung cancer after breast cancer radiation therapy in cigarette smokers. Cancer 73:1615-1620, 1994
33. Inskip P, Stovall M, Flannery J: Lung cancer risk and radiation dose among women treated for breast cancer. J Natl Cancer Inst 86:983-988, 1994
34. Rubino C, de Vathaire F, Diallo I, et al: Radiation dose, chemotherapy and risk of lung cancer after breast cancer treatment. Breast Cancer Res Treat 75:15-24, 2002
35. Prochazka M, Granath F, Ekbom A, et al: Lung cancer risks in women with previous breast cancer. Eur J Cancer 38:1520-1525, 2002
36. Zablotska LB, Neugut AI: Lung carcinoma after radiation therapy in women treated with lumpectomy or mastectomy for primary breast carcinoma. Cancer 97:1404-1411, 2003
37. Ahsan H, Neugut AI: Radiation therapy for breast cancer and increased risk for esophageal carcinoma. Ann Intern Med 128:114-117, 1998
38. Polychemotherapy for early breast cancer: An overview of the randomised trials. Early Breast Cancer Trialists' Collaborative Group. Lancet 352:930-942, 1998
39. Holdener EE, Nissen-Meyer R, Bonadonna G, et al: Second malignant neoplasms in operable carcinoma of the breast. Recent Results Cancer Res 96:188-196, 1984
40. Arriagada R, Rutqvist LE: Adjuvant chemotherapy in early breast cancer and incidence of new primary malignancies. Lancet 338:535-538, 1991
41. Valagussa P, Moliterni A, Terenziani M, et al: Second malignancies following CMF-based adjuvant chemotherapy in resectable breast cancer. Ann Oncol 5:803-808, 1994
42. Herring MK, Buzdar AU, Smith TL, et al: Second neoplasms after adjuvant chemotherapy for operable breast cancer. Am J Clin Oncol 9:269-275, 1986
43. Rubagotti A, Perrotta A, Casella C, et al: Risk of new primaries after chemotherapy and/or tamoxifen treatment for early breast cancer. Ann Oncol 7:239-244, 1996
44. Leone G, Voso MT, Sica S, et al: Therapy related leukemias: Susceptibility, prevention and treatment. Leuk Lymphoma 41:255-276, 2001
45. Leone G, Mele L, Pulsoni A, et al: The incidence of secondary leukemias. Haematologica 84:937-945, 1999
46. Ahuja HG, Felix CA, Aplan PD: Potential role for DNA topoisomerase II poisons in the generation of t(11; 20)(p15;q11) translocations. Genes Chromosomes Cancer 29: 96-105, 2000
47. Felix CA: Leukemias related to treatment with DNA topoisomerase II inhibitors. Med Pediatr Oncol 36:525-535, 2001
48. Tallman MS, Gray R, Bennett JM, et al: Leukemogenic potential of adjuvant chemotherapy for early-stage breast cancer: The Eastern Cooperative Oncology Group experience. J Clin Oncol 13:1557-1563, 1995
49. Diamandidou E, Buzdar AU, Smith TL, et al: Treatment-related leukemia in breast cancer patients treated with fluorouracil-doxorubicin-cyclophosphamide combination adjuvant chemothempy: The University of Texas M.D. Anderson Cancer Center experience. J Clin Oncol 14:2722-2730, 1996
50. Wils JA, Bliss JM, Marty M, et al: Epirubicin plus tamoxifen versus tamoxifen alone in node-positive postmenopausal patients with breast cancer: A randomized trial of the International Collaborative Cancer Group. J Clin Oncol 17:1988-1998, 1999
51. Fumoleau P, Kerbrat P, Romestaing P, et al: Randomized trial comparing six versus three cycles of epirubicin-based adjuvant chemotherapy in premenopausal, node-positive breast cancer patients: 10-year follow-up results of the French Adjuvant Study Group 01 trial. J Clin Oncol 21:298-305, 2003
52. Levine MN, Bromwell VH, Pritchard KI, et al: Randomized trial of intensive cyclophosphamide, epirubicin, and fluorouracil chemotherapy compared with cyclophosophamide, methotrexate, and fluorouracil in premenopausal women with node-positive breast cancer. J Clin Oncol 16:2651-2658, 1998
53. Henderson IC, Berry DA, Demetri GD, et al: Improved outcomes from adding sequential paclitaxel but not from escalating doxorubicin dose in an adjuvant chemotherapy regimen for patients with node-positive primary breast cancer. J Clin Oncol 21:976-983, 2003
54. Citron ML, Berry DA, Cirrincione C, et al: Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer: First report of Intergroup trial C9741/Cancer and Leukemia Group B trial 9741. J Clin Oncol 21:1431-1439, 2003
55. Fisher B, Anderson S, DeCillis A, et al: Further evaluation of intensified and increased total dose of cyclophosphamide for the treatment of primary breast cancer: Findings from National Surgical Adjuvant Breast and Bowel Project B-25. J Clin Oncol 17:3374-3388, 1999
56. Fisher B, Anderson S, Wickerham DL, et al: Increased intensification and total dose of cyclophosphamide in a doxorubicin-cyclophosphamide regimen for the treatment of primary breast cancer: Findings from National Surgical Adjuvant Breast and Bowel Project B-22. J Clin Oncol 15:1858-1869, 1997
57. Riggs BL, Hartmann LC: Selective estrogen-receptor modulators-Mechanisms of action and application to clinical practice. N Engl J Med 348:618-629, 2003
58. Tamoxifen for early breast cancer: An overview of the randomised trials. Early Breast Cancer Trialists' Collaborative Group. Lancet 351:1451-1467, 1998
59. Fisher B, Costantino JP, Wickerham DL, et al: Tamoxifen for prevention of breast cancer: Report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Natl Cancer Inst 90:1371-1388, 1998
60. Fisher B, Dignam J, Wolmark N, et al: Tamoxifen in treatment of intraductal breast cancer: National Surgical Adjuvant Breast and Bowel Project B-24 randomised controlled trial. Lancet 353:1993-2000, 1999
61. Fisher B, Anderson S, Tan-Chiu E, et al: Tamoxifen and chemotherapy for axillary node-negative, estrogen receptor-negative breast cancer: Findings from National Surgical Adjuvant Breast and Bowel Project B-23. J Clin Oncol 19:931-942, 2001
62. Fisher B, Bryant J, Dignam JJ, et al: Tamoxifen, radiation therapy, or both for prevention of ipsilateral breast tumor recurrence after lumpectomy in women with invasive breast cancers of one centimeter or less. J Clin Oncol 20:4141-4149, 2002
63. Fisher B, Costantino J, Redmond C, et al: A randomized clinical trial evaluating tamoxifen in the treatment of patients with node-negative breast cancer who have estrogen-receptor-positive tumors. N Engl J Med 320:479-484, 1989
64. Fisher B, Costantino JP, Redmond CK, et al: Endometrial cancer in tamoxifen-treated breast cancer patients: Findings from the National Surgical Adjuvant Breast and Bowel Project (NSABP) B-14. J Natl Cancer Inst 86:527-537, 1994
65. Bergman L, Beelen MLR, Gallee MPW, et al: Risk and prognosis of endometrial cancer after tamoxifen for breast cancer. Lancet 356:881-887, 2000
66. Fornander T, Hellstrom AC, Moberger B: Descriptive clinicopathologic study of 17 patients with endometrial cancer during or after adjuvant tamoxifen in early breast cancer. J Natl Cancer Inst 85:1850-1855, 1993
67. Magriples U, Naftolin F, Schwartz PE, et al: High-grade endometrial carcinoma in tamoxifen-treated breast cancer patients J Clin Oncol 11:485-490, 1993
68. Fisher B, Dignam J, Bryant J, et al: Five versus more than five years of tamoxifen for lymph node-negative breast cancer: Updated findings from the National Surgical Adjuvant Breast and Bowel Project B-14 randomized trial. J Natl Cancer Inst 93:684-690, 2001
69. Stewart HJ, Forrest AP, Everington D, et al: Randomised comparison of 5 years of adjuvant tamoxifen with continuous therapy for operable breast cancer. The Scottish Cancer Trials Breast Group. Br J Cancer 74:297-299, 1996
70. Delozier T, Spielmann M, Mace-Lesech J, et al: Tamoxifen adjuvant treatment duration in early breast cancer: Initial results of a randomized study comparing short-term treatment with long-term treatment. Federation Nationale des Centres de Lutte Contre le Cancer Breast Group. J Clin Oncol 18:3507-3512, 2000
71. Cummings SR, Eckert S, Krueger KA, et al: The effect of raloxifene on risk of breast cancer in postmenopausal women: Results from the MORE randomized trial. Multiple Outcomes of Raloxifene Evaluation. JAMA 281:2189-2197, 1999
72. Nabholtz JM, Buzdar A, Pollak M, et al: Anastrozole is superior to tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women: Results of a North American multicenter randomized trial. Arimidex Study Group. J Clin Oncol 18:3758-3767, 2000
73. Mouridsen H, Gershanovich M, Sun Y, et al: Superior efficacy of letrozole versus tamoxifen as first-line therapy for postmenopausal women with advanced breast cancer: Results of a, phase III study of the International Letrozole Breast Cancer Group. J Clin Oncol 19:2596-2606, 2001
74. Ellis MJ, Coop A, Singh B, et al: Letrozole is more effective neoadjuvant endocrine therapy than tamoxifen for ErbB-1- and/or ErbB-2-positive, estrogen receptor-positive primary breast cancer: Evidence from a phase III randomized trial. J Clin Oncol 19:3808-3816, 2001
75. The ATAC (Anastrazole, Tamoxifen Alone or in Combination) Trialists' Group: Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: First results of the ATAC randomised trial. Lancer 359:2131-2139, 2003
76. Winer EP, Hudis C, Burstein HJ, et al: American Society of Clinical Oncology technology assessment on the use of aromatase, inhibitors as adjuvant therapy for women with hormone receptor-positive breast cancer: Status report 2002. J Clin Oncol 20:3317-3327, 2002
77. Chlebowski RT, Col N, Winer EP, et al: American Society of Clinical Oncology technology assessment of pharmacologic interventions for breast cancer risk reduction including tamoxifen, raloxifene, and aromatase inhibition. J Clin Oncol 20:3328-3343, 2002
78. Hudis C: Breast cancer and leukemia: The forest for the trees? Ann Surg Oncol 9:717-718, 2002
79. Van de Vijver MJ, He YD, van't Veer LJ, et al: A gene-expression signature as a predictor of survival in breast cancer. N Engl J Med 347:1999-2009, 2002